Key Takeaways
- • Deep Science Ventures operates as a venture creator—not a traditional venture capital fund—combining scientific knowledge with founder-scientists to build deep-tech companies across four sectors: Pharmaceuticals, Climate, Agriculture, and Computation.
- • The firm has built a portfolio of 50 deep-tech companies valued collectively at over $500 million, utilizing a "problem-first" methodology that identifies genuine scientific and planetary challenges as the foundation for venture creation.
- • Deep Science Ventures addresses a structural bottleneck in biotech and deep science: the scarcity of scientists transitioning into founder and company-building roles, a gap the firm tackles through structured founder development and scientific partnership programs.
- • The company employs a "zero-data approach" to early-stage biotech funding, enabling venture creation at earlier discovery stages and reducing traditional data requirements that typically slow innovation commercialization timelines.
- • Operating from five global hubs (London, New York, Amsterdam, Zurich, and additional international locations), Deep Science Ventures combines university research partnerships with venture studio infrastructure to accelerate the path from discovery to scalable commercial enterprises.
Summary
Deep Science Ventures represents a distinct model within the venture capital ecosystem: a venture creator rather than a traditional fund manager, focused on building deep-tech companies from foundational scientific challenges. Founded in 2016 and headquartered in London, the firm operates across Pharmaceuticals, Climate, Agriculture, and Computation sectors, employing approximately 57 professionals across five global offices.
The firm's core value proposition addresses a persistent market inefficiency—the scarcity of scientists-turned-founders. By combining available scientific knowledge with founder-type scientists, Deep Science Ventures systematically identifies problems with genuine scientific and commercial potential, then assembles teams and resources to build ventures around these opportunities. This "problem-first approach" distinguishes the model from deal-flow-dependent venture capital, instead anchoring opportunity identification in rigorous problem validation within academic and institutional research ecosystems.
Deep Science Ventures has demonstrated material traction, having built 50 portfolio companies with a collective valuation exceeding $500 million. The firm's methodology employs what it terms a "zero-data approach" to early-stage biotech funding, enabling venture creation at earlier discovery phases before traditional data accumulation requirements would normally attract capital. This approach reduces time-to-funding and de-risks early-stage scientific ventures by validating market and scientific feasibility before extensive experimental work is required.
The firm's partnership model leverages university research and leading institutions as both scientific resource bases and deal-flow mechanisms, positioning Deep Science Ventures as an infrastructure player in university research commercialization. By operating venture studios globally, the company maintains access to diversified scientific talent pools and geographic markets while maintaining centralized operational and investment discipline.
This venture creator model has emerged as a potential solution to biotech's foundational funding challenges, addressing both capital allocation inefficiency and the structural scarcity of scientific founders willing to transition into company-building roles.
The firm's core value proposition addresses a persistent market inefficiency—the scarcity of scientists-turned-founders. By combining available scientific knowledge with founder-type scientists, Deep Science Ventures systematically identifies problems with genuine scientific and commercial potential, then assembles teams and resources to build ventures around these opportunities. This "problem-first approach" distinguishes the model from deal-flow-dependent venture capital, instead anchoring opportunity identification in rigorous problem validation within academic and institutional research ecosystems.
Deep Science Ventures has demonstrated material traction, having built 50 portfolio companies with a collective valuation exceeding $500 million. The firm's methodology employs what it terms a "zero-data approach" to early-stage biotech funding, enabling venture creation at earlier discovery phases before traditional data accumulation requirements would normally attract capital. This approach reduces time-to-funding and de-risks early-stage scientific ventures by validating market and scientific feasibility before extensive experimental work is required.
The firm's partnership model leverages university research and leading institutions as both scientific resource bases and deal-flow mechanisms, positioning Deep Science Ventures as an infrastructure player in university research commercialization. By operating venture studios globally, the company maintains access to diversified scientific talent pools and geographic markets while maintaining centralized operational and investment discipline.
This venture creator model has emerged as a potential solution to biotech's foundational funding challenges, addressing both capital allocation inefficiency and the structural scarcity of scientific founders willing to transition into company-building roles.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.